The EULAR Scleroderma Trials And Research group (EUSTAR): an international framework for accelerating scleroderma research
- 1 November 2008
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Rheumatology
- Vol. 20 (6), 703-706
- https://doi.org/10.1097/bor.0b013e328311f841
Abstract
Systemic sclerosis has a complex pathogenesis and a multifaceted clinical spectrum without a specific treatment. Under the auspices of the European League Against Rheumatism, the European League Against Rheumatism Scleroderma Trials And Research group (EUSTAR) has been founded in Europe to foster the study of systemic sclerosis with the aim of achieving equality of assessment and care of systemic sclerosis patients throughout the world according to evidence-based principles.EUSTAR created the minimal essential data set, a simple two-page form with basic demographics and mostly yes/no answers to clinical and laboratory parameters, to track patients throughout Europe. Currently, over 7000 patients are registered from 150 centres in four continents, and several articles have been published with the data generated by the minimal essential data set. A commitment of EUSTAR is also to teaching and educating, and for this reason there are two teaching courses and a third is planned for early in 2009. These courses have built international networks among young investigators improving the quality of multicentre clinical trials. EUSTAR has organized several rounds of 'teach the teachers' to further standardize the skin scoring.EUSTAR activities have extended beyond European borders, and EUSTAR now includes experts from several nations. The growth of data and biomaterial might ensure many further fruitful multicentre studies, but the financial sustainability of EUSTAR remains an issue that may jeopardize the existence of this group as well as that of other organizations in the world.Keywords
This publication has 21 references indexed in Scilit:
- Severe fibrosis and increased expression of fibrogenic cytokines in the gastric wall of systemic sclerosis patientsArthritis & Rheumatism, 2007
- Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosisArthritis & Rheumatism, 2007
- Systemic sclerosis associated pulmonary hypertension: improved survival in the current eraHeart, 2006
- Scleroderma: from cell and molecular mechanisms to disease modelsTrends in Immunology, 2005
- Systemic sclerosis in Europe: first report from the EULAR Scleroderma Trials And Research (EUSTAR) group databaseAnnals Of The Rheumatic Diseases, 2005
- Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR RegistryAnnals Of The Rheumatic Diseases, 2004
- Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approachAnnals Of The Rheumatic Diseases, 2003
- Angiogenic and angiostatic factors in systemic sclerosis: increased levels of vascular endothelial growth factor are a feature of the earliest disease stages and are associated with the absence of fingertip ulcersArthritis Research & Therapy, 2002
- Severe organ involvement in systemic sclerosis with diffuse sclerodermaArthritis & Rheumatism, 2000
- Prediction of five-year survival following presentation with scleroderma: Development of a simple model using three disease factors at first visitArthritis & Rheumatism, 1999